We previously generated cancer-specific anti-HER2 mAbs, H2Mab-214/H2CasMab-1 [40] and H2Mab-250/H2CasMab-2 [41], selected from 278 anti-HER2 clones, using HER2 expressed by glioblastoma LN229 cells as the target antigen. This evidence concerns the gene ERBB2 and glioblastoma.